ARIUS announces fourth quarter and year-end fiscal 2007 financi...(p- Preparing to perform preclinical to...)

preparation for filing a Phase I IND application.

CD9 Cancer Stem Cell Program

- CD9 is more highly expressed in leukemia stems cells than normal

stem cells.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model using

cells from human leukemia patients.

- Demonstrated ability to kill cancer stem cells while potentially

leaving normal cells alone.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program continues

to advance in preclinical studies in a variety of cancer indications

as part of a program to move the lead antibody towards the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda under the terms

of the research collaboration agreement, ARIUS has successfully met

its obligations to date and has received all scheduled research

payments from Takeda.

Additional Product Updates

- Currently, ARIUS has antibody programs targeting the MCSP antigen and

37LRP, in addition to several other undisclosed programs.

- Furthered lead optimization for antibodies covering additional novel

targets generated using ARIUS' proprietary FunctionFIRST(TM)

technology.

Other Highlights:

- Granted eight US patents for antibodies and one European patent to

date, and currently have 18 issued or allowed patents covering its

antibody programs and discovery platform and over 185 patents pending

worldwide.

- Promoted Susan Hahn, PhD to the position of Vice President of

Development.

- Appointed Mr. James Rae and Mr. Joseph Zakrzewski to its Board of

Directors and also appointed Mr. Carl Gordon a
'/>"/>